Neuren Pharmaceuticals

NEU · ASX · AUD

20,28 $+0,70 %+0,14 $

Schlusskurs · 2. Oktober 2026

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

Neuren Pharmaceuticals Limited (ASX:NEU): First Dividend Arrives as Phase 3 Investment Accelerates (öffnet in neuem Tab)
Kalkine · 01.10.2026
What Will Its First European Launch Mean for Neuren (ASX:NEU)? (öffnet in neuem Tab)
Kalkine Media · 30.09.2026
Neuren Pharmaceuticals (ASX:NEU): How Could the New Trofinetide Patent Extend Protection? (öffnet in neuem Tab)
Kalkine · 29.09.2026
Neuren Pharmaceuticals (ASX:NEU): US Patent Allowance Supports Potential Trofinetide Protection Extension (öffnet in neuem Tab)
Kalkine · 29.09.2026
What lies ahead for Neuren (ASX:NEU) as FDA talks draw near? (öffnet in neuem Tab)
Kalkine Media · 28.09.2026
Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best? (öffnet in neuem Tab)
The Motley Fool Australia · 21.09.2026
What Could Neuren Pharmaceuticals (ASX:NEU) Mean for Midcaps? (öffnet in neuem Tab)
Kalkine Media · 17.09.2026
Sigma Healthcare, Neuren and Mesoblast: Financial Performance Across ASX Healthcare (öffnet in neuem Tab)
Kalkine · 14.09.2026
ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) (öffnet in neuem Tab)
Kalkine · 14.09.2026
Neuren Pharmaceuticals (ASX:NEU): DAYBUE Royalties and NNZ-2591 Pipeline Define the Growth Story (öffnet in neuem Tab)
Kalkine · 07.09.2026
Neuren Pharmaceuticals (ASX:NEU) Up 1.51% — Royalties and NNZ-2591 Pipeline in the Spotlight (öffnet in neuem Tab)
Kalkine · 04.09.2026